



3HP: Enough "Horse Power" to drive the national TB Infection agenda?

A critical assessment and conversation

Speakers:

Andrey Borisov, MD

*Medical Epidemiologist, Clinical
Research Branch*

Centers for Disease Control & Prevention

David Ashkin, MD

*Medical Director, Co-Principle Investigator
Southeastern National TB Center*

David E. Griffith, MD

Professor of Medicine

University of Texas Health Science Center

Moderator:

Neela D. Goswami, MD, MPH

*Medical Consultant, Field Services Branch
Centers for Disease Control & Prevention*


Objectives

- Interpret current national TB control priorities in the context of the recent CDC recommendations for use of 3HP to achieve optimal care for patients with latent TB infection.
- List important pharmacological aspects of rifapentine alone and in combination with INH including toxicities to prevent primary drug resistance in patients with TB disease.
- Outline the evidence for the efficacy and safety of 3HP treatment of latent TB to apply in the care of patients with latent TB infection.
- Investigate alternative latent TB treatment strategies for patients who are not candidates for 3HP for the purpose of improving their treatment outcomes.

Free LTBI Resources and Materials


Latent TB Infection Resources Online Hub

- One-stop shop for resources, materials, and links to LTBI materials
- Available resources include
 - Key messages
 - Slide sets
 - Images and videos
 - Infographics
 - Communication templates
 - Fact sheets
 - Guidance documents



Latent TB Infection: A Guide for Primary Health Care Providers


- Intended for primary care providers who care for individuals and populations who may be at risk for infection with TB
- Topics include targeted testing, diagnosis of LTBI, and treatment of LTBI



www.cdc.gov/tb/publications/ltbi/default.htm

12-Dose Regimen for Latent TB Infection: Materials for Healthcare Professionals and Patients

- Symptom Checklist and Medication Tracker
- Patient Information Brochure
- Fact Sheet for Clinicians
- FAQs on the 12-Dose Regimen for Latent TB Infection for:
 - Providers
 - Pharmacists



NTCA Provider Guidance: Using the Isoniazid/Rifapentine Regimen to Treat Latent Tuberculosis Infection

NTCA PROVIDER GUIDANCE:
Using the Isoniazid/Rifapentine Regimen to Treat Latent Tuberculosis Infection (LTBI)

IMPORTANT NOTE: Rule out active TB disease in all persons prior to initiating treatment for LTBI.

What is the 12-dose isoniazid/rifapentine regimen (aka "3HP")?

The 3HP regimen consists of 12 once-weekly doses of isoniazid (H) and rifapentine (Priftin®) (P). It provides a safe and effective treatment for LTBI. Rifapentine is a member of the rifamycin class and has many of the same drug-to-drug interactions and side effects as other rifamycins.

What are the advantages of 3HP?

- The 12-dose regimen reduces treatment time by two-thirds (9 months to 3 months) compared to isoniazid.
- Shorter treatment regimens have been shown to have higher rates of completion.
- Weekly dosing offers convenience for many individuals.
- There are lower rates of hepatotoxicity with 3HP than with daily doses of isoniazid.

What are the doses?

Drug*	Weekly Dosage	Maximum dose
Isoniazid	15 mg/kg rounded to nearest 50/100mg in patients ≥12 years	900 mg
	25 mg/kg rounded to the nearest 50/100 mg in patients 2-11 years	
Rifapentine (Priftin®)	10.0 - 14.0 kg = 300 mg	900 mg
	14.1 - 25.0 kg = 450 mg	
	25.1 - 32.0 kg = 600 mg	
	32.1 - 49.9 kg = 750 mg	

*Tables can be crushed and administered with semi-solid food for those unable to swallow pills.

What is completion of therapy?

- Completion of therapy is 12 doses taken in 16 weeks.

NOTE: Near the end of the treatment period, the TB clinician may consider completion of therapy for TB with only 11 once-weekly doses within a 16-week period under rare and insurmountable circumstances in which the patient cannot take an additional (22th) dose.

Does this regimen have to be administered via directly observed therapy (DOT)?

- DOT ensures the highest quality and safety of treatment, and confirms that treatment is completed.
- The healthcare provider should choose the mode of administration, i.e., either DOT versus self-administered therapy (SAT) based on local practice and individual patient attributes and preferences. It is critically important for the clinician to assess the patient's ability to understand risks associated with treatment and procedures to follow if a side effect is suspected, as well as the risk for progression to severe forms of TB disease.

Who is **not recommended for treatment with 3HP?**

- Children under 2 years of age
- Patients with potential for severe or unmanageable drug interactions, including people living with HIV or AIDS on certain antiretroviral therapy regimens
- Persons presumed infected with *M. tuberculosis* that is resistant to isoniazid and/or rifampin
- Pregnant women or women planning to become pregnant during treatment
- Patients who had prior adverse events or hypersensitivity to isoniazid or rifampin or rifapentine

ALERTS:

- Do not confuse rifampin/rifabutin with rifapentine (Priftin®).
- Patients who weigh ≥50kg should take 6 tablets of rifapentine and 3 tablets of isoniazid for a total of 9 pills at a time.
- Some TB experts recommend prescribing vitamin B6 with this regimen due to concerns regarding isoniazid-induced peripheral neuropathy.
- If gHP is self-administered, it is imperative that the patient understands the directions to take all of the pills in the weekly dose at the same time. The patient should not split doses.
- If symptoms suggestive of a systemic drug reaction occur, the patient should stop gHP while the cause is determined.
- Doses should be given at least 72 hours apart and, per expert opinion, there should be no more than 3 doses in 18 days.
- Different from other rifamycins, rifapentine can be taken with food to increase absorption.
- Maintain adequate hydration.

How frequently were toxicities observed with 3HP?

Toxicity	Percentage
Hypersensitivity including flu-like symptoms, headaches, hypotension, near-syncope/syncope	3.8%
Rash	0.8%
Hepatotoxicity	0.4%
Thrombocytopenia	Infrequent
Other toxicities	3.2%

NOTE: Refer to the product insert for a full list of potential side effects. Most side effects occur in the first 4 weeks, although they can continue to occur throughout treatment.

NATIONAL TUBERCULOSIS CONTROLLERS ASSOCIATION

What can an adverse event include and how should I respond?

	Adverse Event	Response	
Moderate to Severe	<ul style="list-style-type: none">• Hypersensitivity• Hypotension• Dizziness or nausea/vomiting (these can be prodrome to syncope)• Syncope/fainting• Hospitalization• Life-threatening event (e.g., fever, chills, headaches, dizziness, musculoskeletal pain)• Thrombocytopenia	<ul style="list-style-type: none">• Shortness of breath• Wheezing• Acute bronchospasm• Urticaria• Petechiae• Purpura• Conjunctivitis• Angioedema• Shock	Discontinue treatment. Conduct prompt clinical assessment with appropriate lab monitoring.
Mild to Moderate	<ul style="list-style-type: none">• Rash• Fever• Pruritus		Continue to monitor the patient closely with a low threshold for discontinuing treatment.

How do I report an adverse event regarding 3HP?

- Report all adverse events to FDA MedWatch at www.fda.gov/Safety/MedWatch/default.htm. 1-888-INFO-FDA (1-888-463-6332)
- Report adverse events leading to death or hospitalization to your health department. Health departments should report these adverse events to the Centers for Disease Control and Prevention at 1-800-232-4636 or LTBI.drugevents@cdc.gov

Are there drug-drug interactions?

Yes, there are common interactions for isoniazid and rifapentine.

- Isoniazid increases blood levels of phenytoin and disulfiram.
- Rifapentine decreases blood levels of oral or implanted hormonal contraceptives, warfarin, sulfonamides, methadone, steroids, some cardiac medications, and certain antiretroviral therapy regimens may have serious drug interactions.

NOTE: Use a drug interactions checker and/or refer to the product insert for a full list of drug-drug interactions.

What type of monitoring do I need to do?

- Evaluate the patient at a monthly visit to identify adverse events and to assess treatment adherence.
- Some experts recommend baseline complete blood count (CBC) due to a possible adverse reaction decreasing the white blood cell count and platelet counts and comprehensive metabolic panel (CMP). Hepatitis panel may also be obtained.
- Baseline hepatic chemistry is recommended for patients with these specific conditions:
 - HIV infection
 - Liver disorders
 - In the postpartum period (≤3 months after delivery)
 - Regular alcohol or injection drug use
- In addition, consider baseline hepatic chemistry for older persons and for persons taking medications for chronic medical conditions.
- If baseline hepatic chemistry testing is abnormal, determine the risk vs. benefit of treatment. If a decision is made to treat, continue with subsequent hepatic chemistry testing until the patient is determined to be stable.
- If baseline hepatic chemistry is within normal limits and the treatment is self-administered, some experts recommend additional laboratory monitoring monthly to ensure that the patient does not develop hepatotoxicity.
- When or after the final dose is taken, conduct a final visit with the patient to monitor for any adverse events.

Whom do I contact with questions or concerns?

- Contact your local or state health department.
- NTCA has an online directory of TB programs at <http://www.tbcontrollers.org/community/statecityterritory/>

NTCA PROVIDER GUIDANCE:
USING THE ISONIAZID/RIFAPENTINE REGIMEN TO TREAT LATENT TUBERCULOSIS INFECTION (LTBI)
NOVEMBER 2018

For references, go to <http://www.tbcontrollers.org/resources/3hp>

Online Publication Ordering System

CDC Home
Centers for Disease Control and Prevention
CDC 24/7: Saving Lives. Protecting People. Saving Money through Prevention.

A-Z Index [A](#) [B](#) [C](#) [D](#) [E](#) [F](#) [G](#) [H](#) [I](#) [J](#) [K](#) [L](#) [M](#) [N](#) [O](#) [P](#) [Q](#) [R](#) [S](#) [T](#) [U](#) [V](#) [W](#) [X](#) [Y](#) [Z](#) <#>

CDC-INFO on Demand - Publications

CDC works 24/7 to provide information that helps protect the health of individuals and communities. Order or download books, fact sheets, pamphlets, and educational materials at CDC-INFO on Demand. If you're ordering fewer than 5 of any item, please consider downloading the items. Visit [CDC Stacks](#) to download materials only available online.

CDC-INFO
Stacks
Contact CDC-INFO
Communiqués con CDC-INFO

Top 10 Orders
Current Month
6 Months
Current Year
All Time

CONCUSSION
Concussions: A Must Read for Young Athletes. Fact sheet.

Filter Publications By:

Programs: [Tuberculosis - For Health Care Providers](#) Languages: [All Languages](#) Material Type: [All Material Types](#) Search for Text: [Search](#)

Found 13 Publications that match your search (viewing 1 - 10).

Publications Per Page: [10](#) [Go](#)

Title	Pub ID	Program	Description	Language	Material Type	Order Amount	Limit	Action
Core Curriculum on Tuberculosis: What the Clinician Should Know	211092	Tuberculosis - For Health Care Providers	The Core Curriculum is intended for use as a self-study guide or reference manual for clinicians and other public health professionals caring for people with or at high risk for TB disease or infection. In addition, the Core Curriculum includes a slide set designed to be useful in developing educational programs. The Core Curriculum was revised in 2013.	English	Guide	0	Limit: 5	Add to Cart International or Over Max Orders
Download Please consider downloading instead of ordering.								
Effective TB Interviewing for Contact Investigation: DVD	220660	Tuberculosis - For Health Care Providers	67-minute video/DVD demonstrates successful interviewing strategies with TB patients and is designed to enhance the knowledge and skills of health care workers who are responsible for conducting TB interviews with patients as part of contact investigations.	English	CD/DVD	0	Limit: 5	Add to Cart International or Over Max Orders
Download More Information								
Effective TB Interviewing for Contact Investigation: Facilitator-Led Training Guide	998214	Tuberculosis - For Health Care Providers	An interactive, skill-building guide designed to improve the knowledge and proficiency of TB staff responsible for conducting the TB interview. Guide is intended for facilitators who will be conducting TB interviewing courses.	English	Guide	Out of Stock		Please consider downloading instead of ordering.
Download								
Effective TB Interviewing for Contact Investigation: Self Study Modules	998215	Tuberculosis - For Health Care Providers	A series of 4 modules, including an overview of the TB interview for contact investigations, basics of communication and patient education, cultural competency, and special interview circumstances.	English	Booklet	Out of Stock		Please consider downloading instead of ordering.
Download More Information								

Cart
Limit: 18 separate publications
Cart is Empty
Publications: 0 Items: 0
[Check Out](#)

Search Order Status
Order #: [Go](#)
Order Date:
List Ordered Items

Contact Us:
Centers for Disease Control and Prevention
1600 Clifton Rd., Atlanta, GA 30333
800-CDC-INFO (800-232-4636)
TTY: (888) 232-6348
[Contact CDC-INFO](#)

<http://wwwn.cdc.gov/pubs/CDCInfoOnDemand.aspx>

More LTBI Educational Products & Tools

By CDC-Funded TB Centers of Excellence

You Can Prevent Tuberculosis

A Patient Educational Video

California Tuberculosis Risk Assessment

Check appropriate risk factor boxes below:

- ☐ **Foreign-born person from a country with an elevated TB rate**
- ☐ **Immunosuppression, current or planned**
- ☐ **Close contact to someone with infectious TB disease at any time**

WHAT PARENTS NEED TO KNOW ABOUT TUBERCULOSIS (TB) INFECTION IN CHILDREN

NEW JERSEY MEDICAL SCHOOL GLOBAL TUBERCULOSIS INSTITUTE

Treating LTBI in Special Situations

Southeastern National Tuberculosis Center

TREATING LTBI IN SPECIAL SITUATIONS

A self-paced, interactive, case-based training

Contact to Drug-Resistant Case
Infants & Children
TNF-Antagonists
Transplantation
Renal Failure
Pregnancy
Hepatitis
HIV/AIDS

Latent TB Infection
I am healthy.

The TB germs are "sleeping" in my body but could "wake up" in the future.

I have no symptoms.

My chest x-ray is normal.

I am not contagious.

I have a positive result on a TB skin test or blood test.

Active TB Disease
I have a serious illness that could kill me if left untreated.

The TB germs have "woken up".

I may have symptoms – cough, fever, weight loss, night sweats.

My chest x-ray may be abnormal.

I may be contagious and could infect other people when TB germs are spread through the air when I cough, laugh or speak.

I may have a positive result on tests of my phlegm.

LTBI Card

Can my **Latent TB Infection** (sleeping germs) wake up and make me sick with **Active TB Disease**?

Yes, and certain factors increase my risk!

- I arrived recently from another country where TB is common.
- I have HIV.
- I was in close contact with someone with active TB disease.
- I have diabetes, kidney failure, or cancer.
- I had surgery to remove part of my stomach.
- I live or work in a hospital, jail, drug rehab center or shelter.
- I use injection drugs.
- I have received an organ transplant.
- I take certain medications that affect my immune system, like prednisone (steroids) or other pills or injections to treat certain types of skin, joint and gastrointestinal conditions.

Yes, I can prevent tuberculosis!
I can take safe, effective medicines.

ASK THE EXPERTS WEBINAR: Clinical Conundrums in LTBI Treatment

A National Webinar

Our session will begin momentarily...

2012

Videos for community health providers

1. Screening of Latent TB Infection

Videos for community health providers

2. Diagnosis of Latent TB Infection

Videos for community health providers

3. Treatment of Latent TB Infection

<http://sntc.medicine.ufl.edu/rtmccproducts.aspx>